Samaritan files IND application for HIV drug
Following discussions and protocol agreement with the FDA, Samaritan will conduct an eight-week Phase II clinical study with SP-6310 in HIV-infected patients with abnormal cortisol levels while on
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).